Advertisement

Advances in Therapy

, Volume 23, Issue 4, pp 615–622 | Cite as

Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes

  • Aysegul Atmaca
  • Olcay Gedik
Article

Abstract

The goal of this study was to compare the effects of lisinopril, losartan, and their combination on microalbuminuria in normotensive patients with type 2 diabetes mellitus. Patients were randomly assigned to 3 groups: group 1 (n=9), group 2 (n=9), and group 3 (n=8) received 10 mg lisinopril, 50 mg losartan, and 10 mg lisinopril plus 50 mg losartan, respectively, each day. For 12 mo, the 24-h urine albumin excretion rate was assessed at 3-mo intervals. At study completion, the urine albumin excretion rate had been reduced significantly in each group (P=.001); however, no significant differences were noted among groups (P=.587). Investigators in the present study have concluded that lisinopril, losartan, and their combination have similar effects on microalbuminuria in normotensive patients with type 2 diabetes mellitus, and that combination therapy does not provide additional benefit.

Keywords

diabetic nephropathy microalbuminuria ACE inhibitors ATII receptor blockers renoprotection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dinneen SF, Gerstein H. The association of microalbuminuria and mortality in non-insulindependent diabetes mellitus: a systematic overview of the literature.Arch Intern Med. 1997; 157:1413–1418.PubMedCrossRefGoogle Scholar
  2. 2.
    McKenna K, Thompson C. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.Scott Med J. 1997;42:99–104.PubMedGoogle Scholar
  3. 3.
    Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy.BMJ. 1992;304:339–343.PubMedCrossRefGoogle Scholar
  4. 4.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for The Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy.N Engl J Med. 1993;329: 1456–1462.PubMedCrossRefGoogle Scholar
  5. 5.
    Parving HH, Rossing P, Hommel E, Smidt UM. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years’ experience.Am J Kidney Dis. 1995;26:99–107.PubMedGoogle Scholar
  6. 6.
    Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensinconverting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study.Arch Intern Med. 1996;156:286–289.PubMedCrossRefGoogle Scholar
  7. 7.
    The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria.Lancet. 1997;349:1787–1792.CrossRefGoogle Scholar
  8. 8.
    Ahmad J, Siddiqui MA. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria.Diabetes Care. 1997;20:1576–1581.PubMedCrossRefGoogle Scholar
  9. 9.
    Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial.Ann Intern Med. 1998;128:982–988.PubMedGoogle Scholar
  10. 10.
    Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N Engl J Med. 2001;345:870–878.PubMedCrossRefGoogle Scholar
  11. 11.
    Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.Circulation. 2002;106:672–678.PubMedCrossRefGoogle Scholar
  12. 12.
    Brenner BM, Cooper ME, de Zeeuw D, et al, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.N Engl J Med. 2001;345:861–869.PubMedCrossRefGoogle Scholar
  13. 13.
    Lewis EJ, Hunsicker LG, Clarke WR, et al, for The Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med. 2001;345:851–860.PubMedCrossRefGoogle Scholar
  14. 14.
    Hebert LA, Falkenhain ME, Nahman NS Jr, Cosio FG, O’Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy.Am J Nephrol. 1999;19:1–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Mogensen CE, Neldam S, Tikkanen I, et al, for the CALM Study Group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.BMJ. 2000;321:1440–1444.PubMedCrossRefGoogle Scholar
  16. 16.
    Tütüncü NB, Gürlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study.Acta Diabetol. 2001;38:157–161.PubMedCrossRefGoogle Scholar
  17. 17.
    Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.Diabetes Care. 2002; 25:95–100.PubMedCrossRefGoogle Scholar
  18. 18.
    Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.Diabetes Care. 2003;26:2268–2274.PubMedCrossRefGoogle Scholar
  19. 19.
    Cetinkaya R, Odabas AR, Selcuk Y. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes.Int J Clin Pract. 2004;58:432–435.PubMedCrossRefGoogle Scholar
  20. 20.
    Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system.Hypertension. 1998;32:387–392.PubMedGoogle Scholar
  21. 21.
    Mogyorósi A, Sonkodi S. AT1 receptor antagonists: a challenge for ACE inhibitors in diabetic nephropathy.Diabetes Metab Res Rev. 1999;15:55–58.PubMedCrossRefGoogle Scholar
  22. 22.
    Pugliese G, Pricci F, Pugliese F, et al. Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells.Diabetes. 1994;43:478–490.PubMedCrossRefGoogle Scholar
  23. 23.
    Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists.N Engl J Med. 1996;334:1649–1654.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science and Business Media and LLC 2006

Authors and Affiliations

  • Aysegul Atmaca
    • 1
  • Olcay Gedik
    • 1
  1. 1.Department of Endocrinology and MetabolismHacettepe University Faculty of MedicineAnkaraTurkey

Personalised recommendations